Messenger RNA technology offers a faster way to develop vaccines to address or prepare for pandemics, and Moderna’s vaccine candidate for avian influenza is on track for Phase 3 testing. But the ...

The US Department of Health and Human Services is terminating a contract with drugmaker Moderna to develop a vaccine to ...

H5 avian flu vaccine study shows positive interim results Company has been notified that HHS will terminate Moderna’s award ...

Avian influenza, also called avian flu or bird flu, is an illness that usually affects only birds. There are many different strains of avian flu: 16 H subtypes and 9 N subtypes. Only those labeled H5, ...

Amidst an ongoing outbreak of a deadly bird flu virus in livestock, the US Department of Agriculture is doing more to prevent ...

The HHS terminated funding for for Moderna's avian influenza vaccine due to safety concerns with mRNA vaccines.

Despite positive results from a Phase I/II trial of its investigational pandemic influenza vaccine, mRNA-1018, Moderna’s ...

Moderna had been awarded over $750 million to develop a vaccine against bird flu, which has been circulating in farm animals ...

The company made the announcement on Wednesday and added they would explore alternatives for late stage development and manufacturing of the vaccine program.

Moderna, Inc. (NASDAQ:MRNA) announced today that its investigational H5 avian influenza vaccine, mRNA-1018, has shown promising interim results in a Phase 1/2 clinical trial involving 300 healthy ...

WASHINGTON, DC – Representative Raja Krishnamoorthi, Ranking Member of the Subcommittee on Healthcare and Financial Services, and other members sent a letter to HHS Secretary Robert F. Kennedy Jr.

The US Department of Health and Human Services (HSS) has terminated a contract previously awarded to Moderna to help advance a vaccine candidate targeting avian influenza, more commonly known as bird ...